However is clearly shown that AURKB proves to be a singular molecular finding in this population, strongly supported by its expression associated with poorer survival rates, pointing out that AURKB may be used potentially as a prognostic biomarker and therapeutic target for pediatric ALL patients. The gene discussed is AURKB; the disease is acute lymphoblastic leukemia.